Sanctuary Advisors LLC Acquires Shares of 1,794 Glaukos Co. (NYSE:GKOS)

Sanctuary Advisors LLC bought a new position in shares of Glaukos Co. (NYSE:GKOS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,794 shares of the medical instruments supplier’s stock, valued at approximately $258,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. HighTower Advisors LLC raised its holdings in shares of Glaukos by 3.3% in the third quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier’s stock valued at $416,000 after purchasing an additional 103 shares during the last quarter. Values First Advisors Inc. purchased a new stake in Glaukos in the 3rd quarter valued at about $25,000. New York State Teachers Retirement System lifted its position in shares of Glaukos by 0.4% during the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock worth $6,272,000 after buying an additional 200 shares in the last quarter. KBC Group NV boosted its stake in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 201 shares during the last quarter. Finally, Inspire Investing LLC grew its holdings in shares of Glaukos by 6.9% in the third quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock valued at $416,000 after acquiring an additional 206 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Activity

In related news, COO Joseph E. Gilliam sold 3,328 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $15,310,024.65. This represents a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,656,707.36. The trade was a 5.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,603 shares of company stock worth $2,605,678. 6.40% of the stock is owned by company insiders.

Glaukos Trading Down 1.0 %

Shares of GKOS stock opened at $151.16 on Friday. Glaukos Co. has a 1 year low of $74.75 and a 1 year high of $153.50. The company’s fifty day simple moving average is $140.18 and its two-hundred day simple moving average is $129.31. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The stock has a market capitalization of $8.33 billion, a price-to-earnings ratio of -50.05 and a beta of 1.03.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm’s revenue for the quarter was up 23.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.50) EPS. As a group, analysts anticipate that Glaukos Co. will post -1.89 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on GKOS shares. Stephens upgraded Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group started coverage on Glaukos in a research note on Friday, December 6th. They set a “buy” rating and a $182.00 target price on the stock. JPMorgan Chase & Co. increased their price target on shares of Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Stifel Nicolaus lifted their price objective on shares of Glaukos from $145.00 to $153.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Finally, Truist Financial increased their target price on shares of Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $145.92.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.